Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Obesity 1Metabolic Syndrome 1Inflammation 1Dyslipidemias 1Diabetes Mellitus, Type 2 1

Interventions

Dipeptidyl-Peptidase IV Inhibitors 3Vildagliptin 2Sulfonylurea Compounds 2Sitagliptin Phosphate 2Rosiglitazone 2Pioglitazone 2Metformin 2voglibose 1somapacitan 1semaglutide 1saxagliptin 1repaglinide 1miglitol 1metahexamide 1meglitinide 1glymidine 1glisoxepide 1gliquidone 1glimepiride 1glibornuride 1empagliflozin 1alogliptin 1Urine Specimen Collection 1Troglitazone 1Tolbutamide 1Tolazamide 1Thiazolidinediones 1Surveys and Questionnaires 1Sodium-Glucose Transporter 2 Inhibitors 1Phenformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Diabetes Mellitus, Type 2 × semaglutide × Clear all
NCT04572165 2024-01-02

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

Novo Nordisk A/S

Unknown
600,000 enrolled

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡